A detailed history of Voya Investment Management LLC transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Voya Investment Management LLC holds 28,547 shares of AVIR stock, worth $94,490. This represents 0.0% of its overall portfolio holdings.

Number of Shares
28,547
Previous 33,286 14.24%
Holding current value
$94,490
Previous $101,000 13.86%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$3.09 - $4.56 $14,643 - $21,609
-4,739 Reduced 14.24%
28,547 $115,000
Q3 2023

Nov 14, 2023

SELL
$3.0 - $3.79 $88,656 - $112,002
-29,552 Reduced 47.03%
33,286 $99,000
Q2 2023

Aug 14, 2023

BUY
$3.21 - $5.06 $3,084 - $4,862
961 Added 1.55%
62,838 $235,000
Q1 2023

May 15, 2023

BUY
$3.0 - $4.97 $21,279 - $35,252
7,093 Added 12.95%
61,877 $207,000
Q4 2022

Feb 14, 2023

BUY
$4.35 - $6.17 $105,822 - $150,097
24,327 Added 79.87%
54,784 $263,000
Q3 2022

Mar 03, 2023

SELL
$5.49 - $8.79 $133,555 - $213,834
-24,327 Reduced 44.41%
30,457 $173,000
Q3 2022

Nov 14, 2022

BUY
$5.49 - $8.79 $11,375 - $18,212
2,072 Added 7.3%
30,457 $173,000
Q2 2022

Aug 15, 2022

BUY
$5.33 - $8.18 $19,379 - $29,742
3,636 Added 14.69%
28,385 $202,000
Q4 2021

Feb 14, 2022

SELL
$7.67 - $44.59 $5,560 - $32,327
-725 Reduced 2.85%
24,749 $221,000
Q2 2021

Aug 16, 2021

BUY
$19.22 - $59.08 $367,486 - $1.13 Million
19,120 Added 300.91%
25,474 $547,000
Q1 2021

May 17, 2021

BUY
$41.42 - $88.44 $63,206 - $134,959
1,526 Added 31.61%
6,354 $392,000
Q4 2020

Feb 16, 2021

BUY
$26.36 - $41.78 $127,266 - $201,713
4,828 New
4,828 $202,000

Others Institutions Holding AVIR

About Atea Pharmaceuticals, Inc.


  • Ticker AVIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,258,600
  • Market Cap $276M
  • Description
  • Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...
More about AVIR
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.